Exclusive Summary

• - Core patents have long expired; outside the US HRS orphan exclusivity (to 2029) most markets have no IP barriers and allow rapid generic entry.
• - Global demand is sizeable with ~0.6–0.8 million acute variceal bleeding episodes and ~0.8–1.2 million HRS-AKI cases annually, concentrated in hospital ED/ICU and hepatology units.
• - Terlipressin is a first-line/standard therapy for AVB and HRS-AKI (listed on WHO EML; strongly endorsed by EASL/Baveno VII), with solid evidence and simple q6h dosing.
• - 0.85 mg base strength matches US labeling and is equivalent to 1 mg acetate, easing cross-market education and tender alignment; registrations in Brazil, Indonesia, Pakistan, and Chile demonstrate multi-agency compliance.
• - Generics typically offer 60–85% cost savings versus brands, delivering substantial course-of-therapy savings and fast uptake by hospitals and payers.